IMAVITA is preclinical efficacy CRO company and an innovating contract research organization proposing preclinical services in the exploration of preclinical models of human pathologies by the use of innovating imaging techniques.
The vision of our company is to propose to pharmaceutical industries, biotechnology companies and other private & public laboratories, innovating solutions in efficacy / toxicity evaluation of active ingredients in laboratory species by the use of non invasive imaging techniques and appropriate imaging analysis for quantitative evaluation of specific imaging biomarkers.

IMAVITA is actually developing the following tools:

• Pre-clinical services testing in laboratory species (induction of pathologies / treatment & sampling phases)
• Imaging techniques like BLI, FLI, OCT, PET/CT, MRI, ultrasonography, etc…
• Images exploitation and analysis for quantitative imaging

IMAVITA is planning to focus its activities in the following domains:

• Drug disposition / PK
• Osteo-articular pathologies
• Dermatology
• Oncology
• Neurology
• Medical Devices

IMAVITA has Research Tax Credit (CIR / “Crédit Impôt Recherche”) accreditation for years 2021 to 2023 (official accreditation available on request).